Lee S. Schwartzberg MD, FACP
Medical Director, West Cancer Center, Memphis, Tennessee; Chief Medical Officer, OneOncologyLee S. Schwartzberg, MD, FACP, is professor of medicine at The University of Tennessee Health Science Center in Memphis, Chief Medical Officer at OneOncology, and medical director of the West Cancer Center, as well as a practicing medical oncologist.
Upon earning his MD degree from the New York Medical College in Valhalla, NY, Dr Schwartzberg completed an internship and a residency in internal medicine at the Cornell University North Shore University Hospital in Manhasset, NY. He then served as chief resident at Memorial Sloan Kettering Cancer Center in New York City and completed a fellowship in medical oncology/hematology.
The author or coauthor of more than 250 publications on medical oncology, hematology, and biosimilars, Dr Schwartzberg has been a leader in and educating healthcare professionals about the potential benefits of biosimilars in oncology practice. He has been very active in the work of the National Comprehensive Cancer Network, having served on its Board of Directors, the Guideline Steering Committee, and the Breast Cancer Guideline Panel, among others. He is past founding chairman of the Association of Community Cancer Centers Immuno-Oncology Institute and the editor-in-chief of the website PracticeUpdate Oncology.
Positions:
Medical Director, West Cancer Center, Memphis, Tennessee
Chief Medical Officer, OneOncology
Degrees:
State University of New York, BA and MS
New York Medical College, MD, FACP
Postgraduate Training:
Intern, North Shore University Hospital, Manhasset, NY
Fellow in medical oncology/hematology, Memorial Sloan-Kettering Cancer Center
Board Certifications:
Medical oncology
Hematology
Clinical Interests:
Medical oncology/hematology
Disclosures
He is a consultant for Amgen, Pfizer, Helsinn, Genentech, BMS, Myriad, AstraZeneca, Spectrum, and Napo.
He is also on the advisory board for Genomic Health Research Funding (Institution): Amgen and DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Dual HER2 Blockade Plus an AI in Postmenopausal Women With HER2+/HR+ Metastatic Breast Cancer
- Oral THC:CBD Cannabis Extract for Refractory Chemotherapy-Induced Nausea and Vomiting
- Olaparib and Durvalumab in Patients With Germline BRCA-Mutated Metastatic Breast Cancer
- Quantifying the Impact of Axillary Surgery and Nodal Irradiation on Breast Cancer–Related Lymphedema and Local Tumor Control
- Neratinib Plus Capecitabine in HER2+ MBC Previously Treated With ≥2 HER2-Directed Regimens
- Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer
- FDA Approves Breast Cancer Treatment That Can Be Administered at Home by Health Care Professional
- FDA Approves Pembrolizumab for Adults and Children With TMB-H Solid Tumors
- ctDNA Markers of Progression in Advanced Breast Cancer Treated With Fulvestrant With or Without Palbociclib
- ASCO: Alpelisib Plus Fulvestrant for PIK3CA-Mutated Breast Cancer After Failure of CDK4/6 Inhibitors